First AD

Second AD

Panelists discuss the challenges encountered in using oral Janus kinase (JAK) inhibitors for patients with alopecia, including issues related to treatment adherence and management of adverse effects.

Challenges With the Use of JAK Inhibitors

Video content above is prompted by the following:

What challenges have you faced, if any, in using oral JAK inhibitors for patients with alopecia?

Recent Advances in the Treatment of Alopecia Areata

Medcast Videos

Recent Advances in Treatment of Alopecia Areata

HCPLive® Peer Exchange panel discussions feature authoritative insights, opinions, and perspectives on important issues facing today's care professionals.

Peer Exchange

Oral JAK inhibitors have emerged as a promising treatment for alopecia, but their use is not without challenges. Clinicians often encounter issues related to patient selection, as not all individuals respond equally to these medications. Monitoring for potential side effects, such as increased risk of infections and changes in blood counts, is crucial. Additionally, long-term safety data is limited, necessitating cautious use and ongoing research. Cost and insurance coverage can also pose significant barriers, impacting patient access to these treatments.

Impact of Alopecia Areata on Quality of Life, and Current Standard of Treatment

JAK Inhibitor Baricitinib for Treatment of Alopecia Areata